Project Grant R01HL188167
Award Date 8/15/26
Completion Date 5/31/30
Dollars Obligated $851K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $1,741,543 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lung injury in pediatric hematopoietic cell transplant recipients. The research examines molecular mechanisms of pulmonary toxicity in pediatric HCT recipients, who experience lung injury in up to 40% of cases with mortality rates of 40% when requiring...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $2,712,905 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop safe, effective, and scalable curative therapies for hemoglobinopathies including sickle cell disease, alpha-thalassemia, beta-thalassemia, and Fanconi anemia by targeting hematopoietic stem cells in vivo using antibody-directed, lipid nanoparticle delivery systems. The research strategy...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $889,932 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer and scale production of red blood cells derived from human induced pluripotent stem cells (iPSCs) for two high-impact applications: alloantibody detection and neonatal transfusion therapy. The project addresses urgent clinical needs in two vulnerable patient populations. Sickle cell disease...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital Corporation, doing business as Boston Children's Hospital, $516,458 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) for Project Grant R01HL187595. The funded research investigates mechanisms of somatic rescue in Fanconi Anemia, a prototypical inherited bone marrow failure syndrome characterized by deficiency in DNA interstrand crosslink repair. The project examines how some...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $889,895 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of biological sex and the innate immune response in neonatal bronchopulmonary dysplasia. The award funds research examining how sex chromosomes and X-chromosome inactivation regulate neonatal lung macrophage polarization in response to hyperoxic injury. The project will establish the...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Children's Hospital of Philadelphia $133,500 on May 5, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate mechanisms of hemoglobin developmental switching as a therapeutic target for sickle cell disease and beta-thalassemia. The project, titled "Control of Hemoglobin Expression by the Chromatin Remodeler CHD7" (R03DK147724), will characterize...
- The National Heart, Lung, and Blood Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded the University of Pennsylvania $635,421 in Project Grant R01HL179069 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into how the transcription factor RUNX1 restrains inflammatory signaling in granulocyte-monocyte progenitors and neutrophils. The research addresses familial platelet disorder...
- The National Heart, Lung, and Blood Institute awarded The Trustees of The University of Pennsylvania $632,561 on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify and optimize signaling pathways that promote the maturation of pre-hematopoietic stem cells into long-term, multi-lineage adult-repopulating hematopoietic stem cells. The research focuses on transforming growth factor beta and bone morphogenetic protein signaling pathways, with emphasis on...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $360,418 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop integrated host-microbe classifiers for diagnosing lower respiratory tract infection in children using metagenomic next-generation sequencing applied to non-invasive samples including nasopharyngeal swabs and whole blood. The project addresses diagnostic gaps in pediatric...
- The National Heart, Lung, and Blood Institute awarded the University of Pennsylvania $100,228 on December 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on the regulation of ribosomal RNA transcription by MYC in hematopoiesis. The funded research dissects how MYC, a developmental transcription factor often dysregulated in disease, directly regulates ribosomal RNA (rRNA) transcription by RNA polymerase I in hematopoietic cells. The work addresses a...